Gilead Sciences (NASDAQ:GILD – Get Free Report) shares surged before the market opened on Thursday. The stock opened at $65.03 after closing at $63.15 the previous day. Gilead Sciences shares were last traded at $65.82 with trading volume of 1,876,508 shares.
Analysts Set New Price Targets
A number of analysts have commented on the company recently. Robert W. Baird reaffirmed their “neutral” rating on shares of Gilead Sciences with a $80.00 price target in a report on Thursday. TD Cowen lowered their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the company in a research report on Friday, April 26th. Wells Fargo & Company lowered their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the company in a research report on Monday, March 4th. Maxim Group lowered their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the company in a research report on Wednesday, May 1st. Finally, StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong buy” rating in a research note on Saturday, April 27. Twelve investment analysts have rated the stock with a “hold” rating, six have given a “buy” rating, and one has given a “strong buy” rating. According to MarketBeat, Gilead Sciences currently has an average rating of “hold” and an average target price of $83.47.
Read the latest Gilead Sciences report
Gilead Sciences shares rose 3.2%
The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The company’s 50-day simple moving average is $65.74 and its 200-day simple moving average is $72.98. The company’s market capitalization is $88.04 billion, its P/E ratio is 196.31, its price-to-earnings growth ratio is 1.27 and its beta is 0.20.
Gilead Sciences (NASDAQ:GILD – Get Free Report) announced its quarterly earnings on Thursday, April 25th. The biopharmaceutical company posted earnings per share of ($1.32) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34%, and a net margin of 1.76%. Revenues for the quarter were $6.69 billion, beating analyst estimates of $6.36 billion. Year-over-year earnings per share were $1.37. Revenues for the quarter were up 5.3% year-over-year. Equity research analysts on average expect Gilead Sciences to post earnings per share of $3.75 for the current fiscal year.
Gilead Sciences announces dividend
The company also recently declared a quarterly dividend, which is scheduled to be paid on Thursday, June 27th. Investors of record on Friday, June 14 will be paid a dividend of $0.77. The ex-dividend date for this dividend is Friday, June 14. On an annualized basis, this equates to a dividend of $3.08 and a yield of 4.36%. Gilead Sciences’ Dividend Payout Ratio (DPR) is currently 855.56%.
Insider Trading at Gilead Sciences
In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a document filed with the Securities and Exchange Commission, which is available on the SEC’s website. The insider owns 0.16% of the company’s shares.
Institutional Investors Invest in Gilead Sciences
Institutional investors have recently modified their holdings of the company’s stock. Altfest LJ & Co. Inc. purchased a new stake in Gilead Sciences Inc. worth $210,000 in the fourth quarter. Federated Hermes increased its holdings in Gilead Sciences Inc. by 4.9% in the fourth quarter. Federated Hermes now holds 3,787,355 shares of the biopharmaceutical company’s stock, valued at $306,814,000, after purchasing an additional 175,925 shares in the last quarter. Charles Schwab Investment Management increased its holdings in Gilead Sciences Inc. by 1.2% in the fourth quarter. Charles Schwab Investment Management now holds 7,281,489 shares of the biopharmaceutical company’s stock, valued at $589,873,000. This comes as it acquired an additional 87,482 shares during the period. Wetzel Investment Advisors Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at $74,000. Finally, Eagle Asset Management Inc. increased its holdings in Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now holds 317,539 shares of the biopharmaceutical company’s stock, valued at $25,724,000, after acquiring an additional 60,697 shares during the period. Institutional investors own 83.67% of the company’s shares.
Gilead Sciences Company Profile
(Get your free report)
Gilead Sciences, a biopharmaceutical company, discovers, develops and commercializes medicines in areas of unmet medical need in the United States, Europe and around the world. The company offers Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs and Atripla products for the treatment of HIV/AIDS, the intravenous infusion Veklury for the treatment of COVID-19, and Epclusa, Harvoni, Vemlidy and Viread for the treatment of viral hepatitis.
Featured Articles
Get Gilead Sciences News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Gilead Sciences and related companies every day with MarketBeat.com’s free email newsletter.
